Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Apellis Pharmaceuticals, Inc. - Common Stock (NQ: APLS )

33.21 +0.07 (+0.21%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Apellis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
17 18 Next >
Apellis Pharmaceuticals to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
Big Pharma is facing a patent cliff that could siphon off billions in revenue. 
Via Investor's Business Daily
Apellis Pharmaceuticals Inc. (NASDAQ: APLS) is a Stock Spotlight on 5/25
Via Investor Brand Network
Needham Maintains Buy Rating for Apellis Pharmaceuticals: Here's What You Need To Know
Via Benzinga
Apellis Pharma Flunks On Primary, Secondary Endpoints In Amyotrophic Lateral Sclerosis Study
Via Benzinga
Why Shares of Annexon Are Plummeting Thursday
Mixed trial results on a geographic atrophy eye drug led investors to sell the biotech stock. 
Via The Motley Fool
Apellis Reports Top-Line Results from Phase 2 MERIDIAN Study in ALS
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Why These 3 Nasdaq Stocks Buckled Today
The FTC's decision to sue to block a high-profile merger is weighing on biotech valuations today. 
Via The Motley Fool
Are Small Caps a Harbinger of Market Declines?
The iShares Russell 2000 ETF outperformed the S&P 500 last week, but that may be short-lived. Small-cap momentum is often a bellwether for broad-market action. 
Via MarketBeat
Topics ETFs Stocks
Exposures US Equities
Top-Notch Biotech Apellis Soars After New Drug Obliterates Sales Views
The company easily beat sales calls on the back of Syfovre, a geography atrophy drug. 
Via Investor's Business Daily
The Latest Analyst Ratings for Apellis Pharmaceuticals
Via Benzinga
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Apellis Pharma's Newly Approved Drug Exceeds Sales Projections, Bullish Analyst Raises Expectations
Apellis Pharmaceuticals Inc (NASDAQ: APLS) reported Q1 revenues of $44.8 million, surpassing the consensus of $26.10 million and  
Via Benzinga
Apellis Pharmaceuticals: Q1 Earnings Insights
Via Benzinga
Apellis Pharmaceuticals Reports First Quarter 2023 Financial Results
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Earnings Preview: Apellis Pharmaceuticals
Via Benzinga
Wedbush Maintains Neutral Rating for Apellis Pharmaceuticals: Here's What You Need To Know
Via Benzinga
9 Analysts Have This to Say About Apellis Pharmaceuticals
Via Benzinga
Apellis Pharmaceuticals to Present at the Bank of America Securities 2023 Healthcare Conference
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Why Apellis Pharmaceuticals, TG Therapeutics, and Viking Therapeutics Were on the Move Today
These three biotech stocks were on the volatile side today. 
Via The Motley Fool
Biotech Buying Bonanza: Iveric Bio Snags $5.9 Billion Deal From Astellas Pharma
The company is working on a treatment for the eye disease known as geographic atrophy. 
Via Investor's Business Daily
Top 5 Health Care Stocks That Could Sink Your Portfolio This Quarter
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
Apellis Pharmaceuticals to Host Conference Call on May 4, 2023, to Discuss First Quarter 2023 Financial Results
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Apellis Presents Phase 3 Functional Analyses of SYFOVRE™ (pegcetacoplan injection) for Geographic Atrophy
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Apellis Announces Validation of Four Marketing Applications for Pegcetacoplan for Geographic Atrophy
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Apellis Partners with Acclaimed Actor Henry Winkler to Raise Awareness of Geographic Atrophy (GA) for the GA Won’t Wait™ Campaign
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.